Pharmacological treatment of adult ADHD in Europe (Q28247634)

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Self concept, action control and ADHD symptoms under methylphenidate treatment in adults with ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Attention-deficit/hyperactivity disorder (ADHD) and driving risk: a review of the literature and a methodological critique

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Attention deficit hyperactivity disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Who cares for patients with attention-deficit/hyperactivity disorder (ADHD)? Insights from Nordbaden (Germany) on administrative prevalence and physician involvement in health care provision

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

Axis I and II comorbidity in adults with ADHD

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F15622975.2011.603229

10.3109/15622975.2011.603229

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

5060131

5060131

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference